Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants
Per Ljungman*, Rafael De la Camara, Noel Milpied, Liisa Volin, Charlotte A. Russell, Adam Crisp, Alison Webster, R. Herrmann, S. Durrant, H. Greinix, A. Ferrant, R. Schots, D. Bron, D. Seleslagh, L. Vindelov, J. Nikoskelainen, E. Gluckman, D. Blaise, J. Cahn, J. ReiffersM. Attal, G. Ehninger, N. Schmitz, H. Link, R. A. Zander, McCann, G. Crotty, R. Or, F. Martelli, S. Tura, P. Di Bartolomeo, F. Mandelli, D. A. Bosi, M. Abecassis, Lacerda, P. Jacobs, M. Sanz, A. Domingo-Albos, C. Rozman, A. Tores-Gomez, F. J. Lopez, G. Öberg, A. Fasth, S. Rödger, P. G. Nilsson, R. E. Clark, H. G. Prentice, R. Powles, S. Proctor, E. J. Kanfer, A. Foot
Dive into the research topics of 'Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants'. Together they form a unique fingerprint.